AI assistant
Medistim Proxy Solicitation & Information Statement 2026
3662_rns_2026-04-14_6fff2d17-3684-4cb4-a39b-2e1df607d9a5.pdf
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
To the shareholders in Medistim ASA
MEDISTIM
NOTICE OF ORDINARY GENERAL MEETING
Medistim ASA will hold its ordinary general meeting Wednesday the 6th of May 2026 at 10.00. The meeting will be held at the company headquarters in Økernveien 94 in Oslo. For shareholders who cannot physically attend, it is possible to give proxy with and without voting instructions to the chairman. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use of proxy, see general information at the bottom of the notice and enclosed proxy forms.
The agenda for the meeting is as follows:
- Approval of the notice, registration of shareholders or persons represented by proxy.
- Appointment of person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary.
- Approval of annual report for 2025.
- Approval of the profit and loss and balance sheet for 2025.
- Approval of the distribution of the profit for the year of TNOK 145,956. The Board of Director’s suggests a dividend of NOK 8.00 per share, total TNOK 146,211 corrected for own shares, and that the remaining TNOK 255 is distributed from other equity to dividend.
- The Board of Directors’ declaration on salary and other remuneration to the management. The Board of Directors’ declaration is included in as an attachment to this notice.
- Approval of fee to the auditor for 2025. Fee to the auditor was in total TNOK 1,667 where TNOK 1,557 was for the audit and TNOK 110 was for other services.
- Election of Board Members.
Three of the Board Members are on election. This is Board Member Peder Strand, Board Member Tove Raanes and Board Member Gry Dahle.
- The Nomination Committee suggests that Peder Strand is re-elected as Board Member for a new term of 2 years to the ordinary General Meeting in 2028.
- The Nomination Committee suggests further that Tove Raanes is re-elected as Board Member for a term of 2 years to the ordinary General Meeting in 2028.
- The Nomination Committee suggests that Gry Dahle is re-elected as Board Member for a term of 2 years to the ordinary General Meeting in 2028.
All candidates are willing to take a term.
- Fees to the Board of Directors.
The Nomination Committee proposes to the General Meeting that the Chairman receives a fee of NOK 550,500. Furthermore, the Nomination Committee proposes that each of the board members will receive a fee of NOK 325,000 for each member. Total fees to the Board of Directors according to the Nomination Committee’s proposal are NOK 2,175,000.
-
The members of the Nomination Committee, Erik Rogstad and Jonathan Schönbäck, are on election. Both members are willing to take a new and it is suggested to the General Assembly that Erik Rogstad and Jonathan Schönbäck are elected as members of the Nomination Committee for two years until the ordinary General Meeting in 2028. Nomination Committee leader Björn Henrik Rasmussen is on election in 2027.
-
It is suggested to the General Meeting that the leader of the Nomination Committee is compensated with NOK 27,000 and that the members are compensated with NOK 22,000. Total purposed fee to the Nomination Committee is TNOK 71,000.
-
The Board has in 2025 appointed a remuneration committee and an audit committee. The remuneration committee consists of 2 members and it is suggested that the leader of the committee is compensated with NOK 35.000 and the
member of the committee is compensated with NOK 30.000. The audit committee consist of 2 members. It is suggested that the leader is compensated with NOK 60.000 and that members are compensated with NOK 45.000.
- Approval of the Board of Directors' suggestion to the General Meeting to renew the Board of Directors' authorization to increase share capital.
A. The Board of Directors is authorized to increase share capital up to NOK 458,433.25 by issuing up to 1,833,733 new shares at par value of NOK 0.25. The share price and other terms when issuing new shares are set by the board of directors. The Board of Directors can increase the share capital once or in several different occasions.
B. In case of a change in par value of the share as a result of a split, fond issue etc, the authorization is adjusted accordingly with the number of shares that can be issued. The share price and other terms are adjusted according to generally known principles for such adjustments, but always within the regulations in the Public Limited Companies Act.
C. The authorization shall also include capital increase against other assets than cash deposits.
D. The shareholders preferential rights to subscribe shares can be set aside by the Board of Directors according to the Public Limited Companies Act § 10-4.
E. The authorization shall include a decision including a fusion according to Public Limited Companies Act § 13-5.
F. The authorization is valid until the next ordinary General Meeting.
In line with the company goals the Board of Director's will assess continuously business opportunities, further development, and expansion of the business. In order to secure flexibility both time wise and for the financing, the Board of Directors prefer to have the authorization from the general meeting to have the opportunity to strengthen equity by issuing new shares against cash deposits or other assets, also in relation to a merger. The authorization can be used to issue shares in relation to convertible loans, acquisition of companies or other commitments in relation to industrial partners or strategic partners.
The purpose of setting aside the preferential rights for existing shareholders to subscribe new shares is to ensure flexibility for the company.
- Approval of the Board of Director's suggestion to renew the power of attorney to purchase own shares on the following conditions:
A. The authorization is valid until the next general meeting.
B. The company can purchase shares at par value up to NOK 458,433.25, which are 1,833,733 shares at today's par value.
C. The highest price per share shall maximum be NOK 500.00 per share.
D. The lowest price per share shall minimum be NOK 0.25 per share.
E. The Board of Directors can freely decide how to purchase the shares as long as the principle for equal treatment is followed.
The purpose of the suggestion is that the company wishes to have available different methods to obtain and secure optimal capital structure.
Notice on participation at the general meeting should be sent to the company one day before the meeting.
Oslo 14th of April 2026
Board of Directors in Medistim ASA
Contact: CEO Kari Eian Krogstad / CFO Thomas Jakobsen
Phone: 23059660
Email: [email protected]
Attachments:
- Form of proxy
- Remuneration report from the Board of Directors
"Firma-/Etternavn, Fornavn "
"c/o"
"Adresse1"
"Adresse2"
"Postnummer, Poststed"
"Land"
Ref no: "Refnr" PIN - code: "Pin"
Notice of General Meeting
General Meeting in Medistim ASA will be held on the 6th of May
2026, Time and place: 10:00 at Økernveien 94 Oslo
Norway
The shareholder is registered with the following amount of shares at summons: "Beholdning" and vote for the number of shares registered in Euronext per Record date 28.04.2026.
The deadline for electronic registration of enrollment, advance votes, proxy of and instructions is 04.05.2025 at 16:00 hours
Electronic registration
Alternatively, "Form for submission by post or e-mail for shareholders who cannot register their elections electronically".
Register during the enrollment/registration period:
- Either through the company's website
https://investor.vps.no/gm/logOn.htm?token=cd36113b9a002f40e2d6f31cc300bbd37cba3751&validTo=1780646400000&oppdragsld=20260317VPP7F5U0 using a reference number and PIN
(for those of you who receive a summons in post-service),
or alternative (available to all) - Log in through VPS Investor services; available at https://investor.vps.no/garm/auth/login or through own account keeper
(bank/broker). Once logged in - choose Corporate Actions – General Meeting – ISIN
You will see your name, reference number, PIN - code and balance. At the bottom you will find these choices:
Enroll Advance Vote Delegate proxy Close
"Enroll" – participate in the meeting on the day
"Advance vote" - If you would like to vote in advance of the meeting
"Delegate Proxy" - Give proxy to the chair of the Board of Directors or another person
"Close" - Press this if you do not wish to register
The general assembly is a physical meeting. If any shareholders wish to participate virtually, please contact the company by e-mail [email protected], so that we facilitate this. Notice to participate virtually must be registered within 04.05.2026. Medistim encourages shareholders to either send in advance vote or give proxy to the chair of the Board of directors or another person.
Please note that the company has a statutory registration deadline, registration after date and time will not be possible.
Ref no: "Refnr"
PIN-code: "Pin"
Form for submission by post or e-mail for shareholders who cannot register their elections electronically.
The signed form is sent as an attachment in an e-mail* to [email protected] (scan this form) or by mail to DNB Bank Registrars Department, P.O Box 1600 centrum, 0021 Oslo. Deadline for registration of advance votes, proxies and instructions must be received no later than 04.05.2026 at 4:00 pm. If the shareholder is a company, the signature must be in accordance with the company certificate. Please note that the company has a statutory registration deadline, forms received after the deadline will not be registered.
*Will be unsecured unless the sender himself secure the e-mail.
"Firma-/Etternavn, Fornavn" shares would like to be represented at the general meeting in Medistim ASA as follows (mark off):
☐ Participate in the meeting representing own shares (do not mark the items below)
☐ Proxy to Chair of the Board of directors or the person he or she authorizes (if you want the proxy to be with instructions please mark "For", "Against" or "Abstain" on the individual items below)
☐ Advance votes («For», «Against» or «Abstain» on the individual items below)
☐ Open proxy to (do not mark items below – agree directly with your proxy solicitor if you wish to give instructions on how to vote)
(enter the proxy solicitors name and e-mail in block letters)
Voting must take place in accordance with the instructions below. Missing or unclear markings are considered a vote in line with the board's and the election committee's recommendations. If a proposal is put forward in addition to, or as a replacement for, the proposal in the notice, the proxy determines the voting.
| Agenda for the Annual General Meeting 06.05.2026 | For | Against | Abstain |
|---|---|---|---|
| 1. Approval of the notice, registration of shareholders or persons represented by proxy. | ☐ | ☐ | ☐ |
| 2. Appointment of person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary proposed in the general meeting. | ☐ | ☐ | ☐ |
| 3. Approval of annual report for 2025. | ☐ | ☐ | ☐ |
| 4. Approval of profit and loss and balance sheet 2025. | ☐ | ☐ | ☐ |
| 5. Approval of the distribution of the profit for the year. | ☐ | ☐ | ☐ |
| 6 a. Approval of remuneration policy to management | ☐ | ☐ | ☐ |
| 6 b. The Board of Director's declaration on salary and other remuneration to the management. | ☐ | ☐ | ☐ |
| 7. Approval of fee to the auditor for 2025. | ☐ | ☐ | ☐ |
| 8. Election of board members: | |||
| 8 a. Peder Strand as Board Member | ☐ | ☐ | ☐ |
| 8 b. Tove Raanes as Board Member | ☐ | ☐ | ☐ |
| 8 c. Gry Dahle as Board Member | ☐ | ☐ | ☐ |
| 9. Fees to the Board. This is according to the Nomination Committee's suggestion. | ☐ | ☐ | ☐ |
| 10. Election of the Nomination Committee members: | |||
| 10 a. Committee member Erik Rogstad | ☐ | ☐ | ☐ |
| 10 b. Committee member Jonathan Schölbäck | ☐ | ☐ | ☐ |
| 11. Compensation to the Nomination Committee's suggestion. | ☐ | ☐ | ☐ |
| 12. Compensation to Committees | |||
| 12.a. Compensation to remuneration committee | ☐ | ☐ | ☐ |
| 12.b. Compensation to audit committee | ☐ | ☐ | ☐ |
| 13. Approval of the Board of Director's suggestion to the general meeting to renew the Board of Director's authorization to increase share capital. | ☐ | ☐ | ☐ |
| 14. Approval of the Board of Director's suggestion to renew the power of attorney to purchase own shares | ☐ | ☐ | ☐ |
The form must be dated and signed
Place
Date
Shareholder's signature
Remuneration to management in 2025
1. introduction
This document also covers guidelines for determining the salary and other remuneration to management employees in accordance with The Public Limited Company Act Section 6-16a second paragraph. The principles described in the document are therefore applicable for 2025 and have not changed since last year.
2. Total compensation
In the below overview 1 and 2 for total compensation, bonus achieved for 2023 was paid in 2024 and bonus achieved in 2024 was paid in 2025. The overview 3 shows the achieved bonus for 2024 to be paid in 2025.
Overview 1 compensation to management in 2024:
| Position | Salary | Bonus | Pension | Share based compensation | Other | Total |
|---|---|---|---|---|---|---|
| VP Marketing | 1 532 492 | 178 476 | 116 173 | - | 15 532 | 1 842 673 |
| VP Medical | 1 538 604 | 208 963 | 93 499 | - | 31 496 | 1 872 561 |
| VP Sales APAC | 1 926 097 | - | 109 719 | - | 40 706 | 2 076 523 |
| VP Development | 1 552 545 | 110 012 | 105 952 | - | 4 480 | 1 772 989 |
| VP QA\Reg | 1 345 238 | 190 847 | 85 507 | - | 4 480 | 1 626 072 |
| VP Sales EMEA | 1 432 563 | 140 106 | 104 438 | - | 32 724 | 1 709 831 |
| VP Operations | 1 444 589 | 152 558 | 99 469 | - | 6 322 | 1 702 938 |
| VP Sales AMERICAS | 2 738 850 | 508 528 | 109 554 | - | - | 3 356 933 |
| VP Innovation | 1 446 643 | 205 373 | 99 878 | - | 22 679 | 1 774 572 |
| CBDO | 1 521 907 | 206 310 | 97 842 | - | 24 128 | 1 850 187 |
| CEO Medistim ASA | 3 341 915 | - | 111 031 | 1 926 000 | 16 146 | 5 395 092 |
| CFO Medistim ASA | 2 142 690 | - | 106 970 | 8 164 | 2 257 824 | |
| 21 964 132 | 1 901 173 | 1 240 032 | 1 926 000 | 206 857 | 27 238 194 |
Entering 2025 there was a change in the management structure in Medistim. In 2024 VP sales positions in EMEA, APAC and AMERICAS reported directly to CEO. From 2025 this changed by hiring a Chief Commercial Officer CCO. The CCO reports directly to CEO and the VP sales positions report to CCO. This explains why top management goes from 12 people to 8.
Overview 2 compensation to management in 2025:
| Position | Salary | Bonus | Pension | Other | Total |
|---|---|---|---|---|---|
| CEO Medistim ASA | 3 309 120 | 1 393 738 | 140 718 | 22 870 | 4 866 446 |
| CFO Medistim ASA | 2 185 067 | - | 135 839 | 8 268 | 2 329 174 |
| VP QA\Reg | 1 560 465 | 282 134 | 105 479 | 1 697 | 1 949 775 |
| VP Operations | 1 509 587 | 63 564 | 125 699 | 4 392 | 1 703 242 |
| VP Innovation | 1 546 347 | 192 538 | 128 592 | 14 082 | 1 881 559 |
| VP Development | 1 286 296 | 103 136 | 94 594 | 3 768 | 1 487 794 |
| VP Marketing | 1 577 963 | 167 321 | 143 607 | 23 772 | 1 912 663 |
| CCO | 1 915 431 | - | 213 434 | - | 2 128 865 |
| 14 890 276 | 2 202 431 | 1 087 962 | 78 849 | 18 259 518 |
Overview 3 accrued bonus to management based upon 2025 results to be paid in 2026:
| Position | Bonus |
|---|---|
| CEO | 1 473 214 |
| CFO | 581 050 |
| CCO | 957 600 |
| VP Operations | 234 718 |
| VP R&D | - |
| VP QA/reg | - |
| VP Marketing | 282 438 |
| VP Innovation | 269 515 |
| Sum | 3 798 535 |
3. Share based remuneration
Share program to management
In April 2025 The General meeting approved the financial assistance related to the long term share based incentive plan for senior management. The general meeting approved that the company make a loan with a limit of NOK 10,000,000 available to senior executives in Medistim ASA according to allmennaksjeloven § 8-10. The loan framework can only be used for partial financing of share purchases that Medistim senior executives has been offered. The program gives executive management the opportunity to purchase Medistim shares at a 25% discount with a lock in period of at least 3 years, or as long as the executive is employed. The exercise of the offer will be limited in time and will only be used once. The share program did not include CEO since she has a separate arrangement. The below list gives an overview of shares purchased and the financing of it:
| Position | Shares purchased in NOK | Match 25% in NOK | Total purchase of shares in NOK | Number of shares | Loan share program |
|---|---|---|---|---|---|
| Team leader HW | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| Team leader SW | 150 000 | 37 500 | 187 500 | 928 | - |
| Tech lead | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| Bus & Prod mgr Cardiac | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| Bus & Prod mgr Vascular | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| Medical advisor | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| Fin Mgr | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| VP Marketing | 100 000 | 25 000 | 125 000 | 619 | 50 000 |
| VP Sales APAC | 300 000 | 75 000 | 375 000 | 1 856 | 300 000 |
| VP QA\REG | 800 000 | 200 000 | 1 000 000 | 3 772 | 800 000 |
| VP R&D | 800 000 | 200 000 | 1 000 000 | 3 772 | 800 000 |
| VP Innovation | 300 000 | 75 000 | 375 000 | 1 856 | - |
| CFO | 400 000 | 100 000 | 500 000 | 2 475 | 400 000 |
| Total | 4 650 000 | 1 162 500 | 5 812 500 | 26 414 | 4 150 000 |
CCO has a separate agreement since he is located in UK. He could purchase 3 shares and get 2 for free if in position after 3 years. The CCO purchased 3322 shares in November 2025 and will if in position receive another 1474 shares.
Share program to CEO
The CEO has a share program similar to management described above. The CEO 100% owned company, K2 Consulting AS, may purchase the shares from Medistim ASA with a lock in period of 3 years at a 25% discount. To finance the purchase, Medistim gives CEO a loan and when the lock in period has ended, she is given a bonus equal to the loan amount. Future grants in the CEO share program is on the same terms. Under the program CEO has received 26.000 shares 25% discount in the period from 2023 to 2025 and a 3 year lock in period.
Shares given in 2023 was 8 000 shares at NOK 177,19 per share if in position 01.01.2026
Shares given in 2024 was 8 000 shares at NOK 144,56 per share if in position 01.01.2027
Shares given in 2025 was 10 000 shares at NOK 129,78 per share if in position 01.01.2028
4. Use of right to reclaim
Not applicable in Medistim.
5. Information on how the remuneration complies with the remuneration policy and how performance criteria were applied.
On a yearly basis the company update its 3 year strategy plan. The review is performed during the board meeting in June. The updated strategy plan is the basis for the budget the following year. As part of the budget, which sets the financial goal for the coming year, an annual Goals and objectives (G & O) is also updated. The G & O breaks down the strategy plan and the budget down to departments goal for the year in question. Management bonus is linked to the budget for financial targets and the G & O when it is not financial targets. The table below shows the management position and criteria for bonus in 2025 and to what extent the criteria are achieved. The criteria related to G & O will vary based upon the G & O for the relevant year. Se table below:
| Position | Bonus criteria | Weigt of the criteria | Type of measure | Target/Max bonus | Achieved |
|---|---|---|---|---|---|
| VP Marketing | Financial targets | 60 % | Absolute target and linear scale | 25% of base salary | 80 % |
| Approved internal project | 40 % | Absolute measure | |||
| VP Development | Financial targets | 60 % | Absolute target | 25% of base salary | 0 % |
| New in position Q4 25 | Approved internal project | 40 % | Absolute measure | ||
| VP QA\Reg | Financial targets | 60 % | Absolute target | 25% of base salary | 0 % |
| New in position Q4 25 | Approved internal project | 40 % | Absolute measure | ||
| VP Operations | Financial targets | 60 % | Absolute target | 25% of base salary | 70 % |
| Approved internal project | 40 % | Absolute measure | |||
| VP Innovation | Financial targets | 60 % | Absolute target | 25% of base salary | 80 % |
| Approved internal project | 40 % | Absolute measure | |||
| CCO | Financial targets | 100 % | Linear scale | 50% of base salary | 100 % |
| CEO Medistim group | Linear EBIT measure | 100 % | EBIT from last year + 37% | 50% of base salary | 100 % |
| CFO Medistim Group | Linear EBIT measure | 100 % | EBIT from last year + 37% | 30% of base salary | 100 % |
6. Deviation from the remuneration policy.
Nothing to report
7. Comparative information on change on remuneration.
| Yearly change | Compensation in TNOK | RFY-4 vs. RFY-5 | Compensation in TNOK | RFY-3 vs. RFY-4 | Compensation in TNOK | RFY-2 vs. RFY-3 | Compensation in TNOK | RFY-1 vs. RFY-2 | Compensation in TNOK | RFY vs. RFY-1 | Comment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total compensation | |||||||||||
| VP Marketing | 1.489 | 2,32 % | 1.834 | 23,20 % | 1.873 | 2,15 % | 1.843 | -1,64 % | 1.912 | 3,77 % | |
| VP Development | 1.507 | 1,85 % | 1.784 | 18,36 % | 1.757 | -1,52 % | 1.773 | 0,90 % | 556 | -68,62 % | New in position Q4 2025 |
| VP QA\Reg | 1.270 | 2,32 % | 1.597 | 25,77 % | 1.604 | 0,48 % | 1.626 | 1,35 % | 557 | -65,73 % | New in position Q4 2025 |
| VP Operations | 1.432 | 1,85 % | 1.580 | 10,36 % | 1.667 | 5,53 % | 1.703 | 2,13 % | 1.667 | -2,13 % | |
| VP Innovation | 1.412 | n.a | 1.860 | 31,75 % | 1.910 | 2,68 % | 1.775 | -7,09 % | 1.833 | 3,30 % | New position in year 4 |
| CEO Medistim Group | 2.129 | New in position in 2025 | |||||||||
| CEO Medistim group | 6.395 | -0,14 % | 8.866 | 38,63 % | 7.206 | -18,73 % | 5.395 | -25,13 % | 4.866 | -9,80 % | |
| CFO Medistim Group | 2.001 | -15,87 % | 2.643 | 32,12 % | 2.774 | 4,97 % | 2.258 | -18,62 % | 2.299 | 1,82 % | |
| Company EBIT TNOK | 116 278 | 141 251 | 131 442 | 131 076 | 196 196 | ||||||
| Average compensation employees | 3,50 % | 4,00 % | 6,00 % | 5,60 % | 4,50 % | ||||||
| Total number of employees | 116 | 132 | 152 | 154 | 159 |
BDO AS
Bygdøy Allé 2
PO Box 1704 Vika
0121 Oslo
Norway
To the General Meeting of Medistim ASA
Independent auditor’s assurance report on report on salary and other remuneration to directors
Opinion
We have performed an assurance engagement to obtain reasonable assurance that Medistim ASA’s report on salary and other remuneration to directors (the remuneration report) for the financial year ended 31. December 2025 has been prepared in accordance with section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation.
In our opinion, the remuneration report has been prepared, in all material respects, in accordance with section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation.
Board of directors’ responsibilities
The board of directors is responsible for the preparation of the remuneration report and that it contains the information required in section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation and for such internal control as the board of directors determines is necessary for the preparation of a remuneration report that is free from material misstatements, whether due to fraud or error.
Our independence and quality control
We are independent of the company as required by laws and regulations and the International Ethics Standards Board for Accountants’ Code of International Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. The firm applies International Standard on Quality Management, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.
Auditor’s responsibilities
Our responsibility is to express an opinion on whether the remuneration report contains the information required in section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation and that the information in the remuneration report is free from material misstatements. We conducted our work in accordance with the International Standard for Assurance Engagements (ISAE) 3000 - “Assurance engagements other than audits or reviews of historical financial information”.
We obtained an understanding of the remuneration policy approved by the general meeting. Our procedures included obtaining an understanding of the internal control relevant to the preparation of the remuneration report in order to design procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal
BDO AS, a Norwegian limited liability company, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms. The Register of Business Enterprises: NO 993 606 650 VAT.
BDO
control. Further we performed procedures to ensure completeness and accuracy of the information provided in the remuneration report, including whether it contains the information required by the law and accompanying regulation. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
BDO AS
Erik H. Lie
State Authorised Public Accountant
(This document is signed electronically)
BDO AS, a Norwegian limited liability company, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms. The Register of Business Enterprises: NO 993 606 650 VAT.
PENN30
Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo™ - sikker digital signatur". De signerende parter sin identitet er registrert, og er listet nedenfor.
"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."
Erik Helge Lie
State Authorised Public Accountant
Serienummer: bankid.no no_bankid:9578-5995-4-155606
IP: 188.95.xxx.xxx
2026-04-14 11:38:33 UTC
GES
bankID
Dette dokumentet er signert digitalt via Penneo.com. De signerte dataene er validert ved hjelp av den matematiske hashverdien av det originale dokumentet. All kryptografisk bevisføring er innebygd i denne PDF-en for fremtidig validering.
Dette dokumentet er forseglet med et kvalifisert elektronisk segl. For mer informasjon om Penneos kvalifiserte tillitstjenester, se https://eutl.penneo.com.
Slik kan du bekrefte at dokumentet er originalt
Når du åpner dokumentet i Adobe Reader, kan du se at det er sertifisert av Penneo A/S. Dette beviser at innholdet i dokumentet ikke har blitt endret siden tidspunktet for signeringen. Bevis for de individuelle signatørenes digitale signaturer er vedlagt dokumentet.
Du kan bekrefte de kryptografiske bevisene ved hjelp av Penneos validator, https://penneo.com/validator, eller andre valideringsverktøy for digitale signaturer.